Alexion Pharmaceuticals
↗Boston, USA
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions. It is a pioneer in the development of complement-mediated therapies, having launched the first-in-class C5 inhibitor Soliris. The company was acquired by AstraZeneca in July 2021 for $39 billion and now operates as the dedicated rare disease unit of the group.
Alexion's portfolio focuses on hematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company is headquartered in Boston's Seaport District and maintains significant R&D and manufacturing operations in New Haven, Connecticut, and Dublin, Ireland.
CLASSIFICATION
SIZE & FINANCIALS
Employees:10000+
Revenue:$7B-$8B (Rare Disease Unit)
Founded:1992
Ownership:subsidiary
Status:acquired
FUNDING
Stage:Acquired
Total Raised:$39B (Acquisition Value)
Investors:AstraZeneca
STOCK
Exchange:NASDAQ
Ticker:AZN (Parent)
Market Cap:$200B+ (AstraZeneca Group)
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (Ultomiris, Soliris)
Modalities:mAb, Small molecule, Enzyme replacement therapy, Gene therapy, siRNA
Active Trials:284
Trial Phases:Phase 1: 303 | Phase 2: 85 | Phase 3: 82 | Phase 4: 8
FDA Approvals:6
EMA Approvals:5
CORPORATE STRUCTURE
Parent Company:AstraZeneca
Acquired By:AstraZeneca (2021-07-01)
Subsidiaries:LogicBio Therapeutics, Amolyt Pharma, Syntimmune
Key Partnerships:JCR Pharmaceuticals (Neurodegenerative diseases), Genomenon (AI for rare disease diagnosis), Zaloni (DataOps), MCPHS (Fellowship programs)
COMPETITION
Position:Leader
Competitors:Roche (Chugai), Amgen, Apellis Pharmaceuticals, Sanofi, Novartis
LEADERSHIP
Key Executives:
Marc Dunoyer - CEO
Gianluca Pirozzi - SVP, Head of Development, Regulatory and Safety
Scientific Founders:Leonard Bell, Stephen Squinto
Board Members:Pascal Soriot (AstraZeneca CEO), Marc Dunoyer
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Alexion Pharmaceuticals. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.